An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity.
Gastric cancer is the second most frequent cause of death from cancer in the world and the leading cause of death from cancer in China. In September 1995, we launched a randomized multi-intervention trial to inhibit the progression of precancerous gastric lesions in Linqu County, Shandong Province, an area of China with one of the world's highest rates of gastric cancer. Treatment compliance was measured by pill counts and quarterly serum concentrations of vitamin C, vitamin E and S-allyl cysteine. In 1999, toxicity information was collected from each trial participant to evaluate treatment-related side-effects during the trial. Compliance rates were 93% and 92.9% for 39 months of treatment with the vitamins/mineral and garlic preparation, respectively. The means for serum concentrations of vitamins C and E were 7.2 microg/ml and 1695 microg/dl among subjects in the active treatment groups compared with 3.1 microg/ml and 752 microg/dl among subjects in the placebo treatment group, respectively. No significant differences in side-effects were observed between the placebo treatment group and the vitamins/mineral and garlic preparation treatment groups during the 39-month trial period.
You
W C
WC
National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD 20892, USA. youw@exchange.nih.gov
Chang
Y S
YS
Heinrich
J
J
Ma
J L
JL
Liu
W D
WD
Zhang
L
L
Brown
L M
LM
Yang
C S
CS
Gail
M H
MH
Fraumeni
J F
JF
Xu
G W
GW
D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000627:therapeutic use; D002681:China / Q000453:epidemiology; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005737:Garlic / Q000627:therapeutic use; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D010349:Patient Compliance; D010406:Penicillins / Q000627:therapeutic use*; D008517:Phytotherapy; D010946:Plants, Medicinal; D011230:Precancerous Conditions / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control*; D015995:Prevalence; D012643:Selenium / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control*; D016896:Treatment Outcome; D014810:Vitamin E / Q000627:therapeutic use; D019207:beta Carotene / Q000627:therapeutic use
D000975:Antioxidants; D010406:Penicillins; D019207:beta Carotene; D014810:Vitamin E; D000658:Amoxicillin; D012643:Selenium; D009853:Omeprazole; D001205:Ascorbic Acid